SPOTLIGHT: J&J's risky infringement defense flops

Here's a new infringement-suit tactic: say your product isn't as safe as your opponent's, so it falls outside the patent's safety profile. That's what Johnson & Johnson said in its defense against Boston Scientific claims of stent-related poaching. It didn't work. The judge said that the infringement ruling stands. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.